Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Eli Lilly stock plunges. To find out what lies ahead for Eli Lilly in this increasingly competitive environment, visit CDS.

Eli Lilly’s weight-loss pill, orforglipron, shows promising results in trials, offering a needle-free alternative to injectables like Ozempic and Mounjaro. In a major study, people who took the drug ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump's tariffs taking effect on dozens of countries ...

U.S. stocks drifted to a mixed finish as President Donald Trump’s tariffs on dozens of countries had only a muted effect on ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Recent health news highlights include Kenvue cutting its sales forecast amid strategic changes, Eli Lilly raising its profit ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...